Tony Chen, MD
Urology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Offices
- 4
Offices
4 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chen’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A166904 · Current
Licensed to practise in California · since 2019 · expires 2027-11-30 · University of California, San Diego School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$100,632
Medicare paid this office $100,632 for 385 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (45+ min) | 195 | $23,912 | $123 |
| Return visit (30+ min) | 169 | $20,503 | $100 |
| Diagnostic exam of bladder and urethra using an endoscope | 51 | $5,068 | $97 |
| Long return visit (40+ min) | 15 | $2,140 | $143 |
| Short return visit (20+ min) | 27 | $1,708 | $59 |
See all 8 services
| New patient visit (45+ min) | 195 | $23,912 | $123 |
| Return visit (30+ min) | 169 | $20,503 | $100 |
| Diagnostic exam of bladder and urethra using an endoscope | 51 | $5,068 | $97 |
| Long return visit (40+ min) | 15 | $2,140 | $143 |
| Short return visit (20+ min) | 27 | $1,708 | $59 |
| Ultrasound scan of pelvic region through rectum | 11 | $642 | $58 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 19 | $297 | $15 |
| Simple bladder irrigation and/or instillation | 13 | $244 | $19 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Prostate resection | 1-10 | None |
Who their Medicare patients are
385 Original Medicare patients in 2024. Average age 74 · Under 65 5% · 85 and older 8% · Women 10% · Also on Medicaid 13% · Health risk score 1.14. At or below the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 66% · Coronary heart disease 27% · Cancer 25% · Chronic kidney disease 24% · Diabetes 20% · Atrial fibrillation 19% · Depression 12% · Heart failure 11% · COPD 8% · Stroke 6% · Dementia 3%.
The office billed $852,705, Medicare allowed $133,978 and paid $100,632; for 4,420 services of 49 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 385 | 4,420 | 74 | 1.14 | $852,705 | $100,632 |
| 2023 | 380 | 654 | 74 | 1.15 | $417,192 | $68,619 |
| 2022 | 261 | 492 | 75 | 1.08 | $348,550 | $46,697 |
| 2021 | 116 | 174 | 72 | 1.38 | $61,638 | $16,004 |
| 2020 | 57 | 87 | 74 | 1.81 | $52,945 | $7,434 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| New patient visit (45+ min) | 216 | $25,758 | $119 |
| Return visit (30+ min) | 139 | $15,443 | $88 |
| Diagnostic exam of bladder and urethra using an endoscope | 36 | $3,557 | $99 |
| Long return visit (40+ min) | 25 | $3,279 | $131 |
| New patient visit (60+ min) | 11 | $1,836 | $167 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 11 | $1,727 | $157 |
| Short return visit (20+ min) | 18 | $1,261 | $70 |
| Telehealth originating site facility fee | 32 | $718 | $22 |
2022: 6 services
| New patient visit (45+ min) | 159 | $17,753 | $112 |
| Return visit (30+ min) | 97 | $11,011 | $85 |
| Long return visit (40+ min) | 27 | $4,195 | $135 |
| Diagnostic exam of bladder and urethra using an endoscope | 31 | $2,352 | $74 |
| Short return visit (20+ min) | 12 | $549 | $46 |
| Simple bladder irrigation and/or instillation | 16 | $255 | $15 |
2021: 5 services
| New patient visit (45+ min) | 49 | $5,905 | $121 |
| New patient visit (45+ min) | 25 | $2,751 | $110 |
| Return visit (30+ min) | 19 | $1,704 | $85 |
| Return visit (30+ min) | 16 | $1,313 | $77 |
| Electronic assessment of bladder emptying | 12 | $93 | $8 |
2020: 2 services
| New patient visit (45+ min) | 31 | $3,629 | $117 |
| Return visit (30+ min) | 11 | $802 | $73 |
Drugs they prescribed that Part D paid
$45,838
Pharmacies billed $45,838 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
467 generic and 43 brand-name prescriptions · $45,838 in drug cost · 29 antibiotic prescriptions to 26 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 25 | $24,214 | $969 |
| Testosterone | 44 | $4,289 | $97 |
| Tamsulosin | 174 | $3,263 | $19 |
| Finasteride | 69 | $1,479 | $21 |
| Alfuzosin Hcl Er | 20 | $631 | $32 |
See all 10 drugs
| Myrbetriq | 25 | $24,214 | $969 |
| Testosterone | 44 | $4,289 | $97 |
| Tamsulosin | 174 | $3,263 | $19 |
| Finasteride | 69 | $1,479 | $21 |
| Alfuzosin Hcl Er | 20 | $631 | $32 |
| Testosterone Cypionate | 12 | $605 | $50 |
| Pentoxifylline | 25 | $451 | $18 |
| Tadalafil | 14 | $367 | $26 |
| Sildenafil Citrate | 25 | $279 | $11 |
| Ibuprofen | 12 | $72 | $6 |
Year by year
| 2024 | 510 | 193 | None | 8% | $45,838 |
| 2023 | 465 | 156 | None | None | $54,018 |
| 2022 | 391 | 108 | None | 17% | $38,134 |
| 2021 | 214 | 70 | None | 13% | $18,785 |
| 2020 | 111 | 59 | 13% (14) | 13% | $6,244 |
| 2019 | 52 | 30 | 25% (13) | None | $2,248 |
| 2018 | 71 | 34 | 20% (14) | None | $3,989 |
| 2017 | 101 | 52 | 22% (22) | 12% | $4,134 |
| 2016 | 81 | 46 | 40% (32) | None | $1,647 |
| 2015 | 93 | 51 | 27% (25) | 15% | $2,747 |
| 2014 | 33 | 18 | 49% (16) | None | $281 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Myrbetriq | 36 | $36,794 | $1,022 |
| Testosterone | 45 | $4,055 | $90 |
| Tamsulosin | 126 | $3,310 | $26 |
| Estradiol | 11 | $1,943 | $177 |
| Trospium Chloride | 15 | $1,565 | $104 |
| Finasteride | 55 | $1,109 | $20 |
| Testosterone Cypionate | 11 | $607 | $55 |
| Pentoxifylline | 11 | $228 | $21 |
| Nitrofurantoin Mono-Macro | 15 | $158 | $11 |
| Alfuzosin Hcl Er | 14 | $107 | $8 |
| Sildenafil Citrate | 30 | $95 | $3 |
| Sulfamethoxazole-Trimethoprim | 13 | $67 | $5 |
2022: 9 drugs
| Myrbetriq | 49 | $27,176 | $555 |
| Tamsulosin | 108 | $2,107 | $20 |
| Trospium Chloride | 13 | $1,571 | $121 |
| Testosterone | 16 | $1,007 | $63 |
| Testosterone Cypionate | 14 | $434 | $31 |
| Finasteride | 18 | $364 | $20 |
| Oxybutynin Chloride | 12 | $341 | $28 |
| Nitrofurantoin Mono-Macro | 19 | $333 | $18 |
| Pentoxifylline | 11 | $164 | $15 |
2021: 7 drugs
| Myrbetriq | 16 | $8,701 | $544 |
| Testosterone | 16 | $3,410 | $213 |
| Tamsulosin | 48 | $667 | $14 |
| Pentoxifylline | 15 | $649 | $43 |
| Oxybutynin Chloride Er | 11 | $459 | $42 |
| Finasteride | 11 | $136 | $12 |
| Clotrimazole-Betamethasone | 14 | $87 | $6 |
2020: 2 drugs
| Oxybutynin Chloride Er | 13 | $433 | $33 |
| Tamsulosin | 17 | $222 | $13 |
2017: 3 drugs
| Tamsulosin | 20 | $401 | $20 |
| Sulfamethoxazole-Trimethoprim | 11 | $76 | $7 |
| Hydrocodone-Acetaminophen | 11 | $40 | $4 |
2015: 1 drug
| Oxycodone | 18 | $216 | $12 |
2014: 1 drug
| Oxycodone | 14 | $139 | $10 |
Money from drug and device companies
$99 in 2025
| 2025 | 3 | 3 | None | $99 |
| 2024 | 4 | 6 | None | $501 |
| 2023 | 2 | 6 | None | $409 |
| 2022 | 1 | 7 | None | $586 |
| 2021 | 3 | 9 | None | $1,454 |
| 2020 | 2 | 6 | None | $1,628 |
| 2019 | 1 | 1 | None | $156 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | Ams 700 | $47 | 1 payment
|
| Blue Earth Diagnostics | Posluma | $34 | 1 payment
|
| Ambu | None | $18 | 1 payment
|
See all 3 published payments
| Boston Scientific | Meals · 2025-12-19 | Ams 700 | $47 |
| Blue Earth Diagnostics | Meals · 2025-09-09 | Posluma | $34 |
| Ambu | Meals · 2025-01-27 | None | $18 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $501
| Boston Scientific | Lithovue | $340 | 3 payments
|
| Laborie Medical Technologies | Optilume Bph Drug Coated Balloon Catheter | $90 | 1 payment
|
| Accord Healthcare | Camcevi | $47 | 1 payment
|
| Axonics | Axonics | $24 | 1 payment
|
2023: $409
| Coloplast | Titan | $295 | 4 payments
|
| Boston Scientific | Lithovue | $114 | 2 payments
|
2022: $586
| Boston Scientific | Advance Xp | $586 | 7 payments
|
2021: $1,454
| Coloplast | Titan | $1,251 | 6 payments
|
| Boston Scientific | General - Erectile Dysfunction | $103 | 2 payments
|
| Olympus America | Itind System | $101 | 1 payment
|
2020: $1,628
| Intuitive Surgical | Da Vinci Surgical System | $1,541 | 5 payments
|
| Boston Scientific | Ams | $87 | 1 payment
|
2019: $156
| Medtronic USA | Interstim | $156 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1013335512
- Licence
- CA A166904California A166904: Current · expires 2027-11-30
- Trained
- University of California, San Diego School of Medicine, 2014
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2014-04-01
- NPI last updated
- 2024-04-29
- NPI record certified
- 2024-04-29
This is when the NPI record was last certified, not a medical board exam.